Dapagliflozin in the therapy of chronic heart failure of functional class II–III with moderately reduced ejection fraction
- Authors: Zaporozhskaya N.V.1, Kartashova E.A.1, Zheleznyak E.I.1
-
Affiliations:
- Rostov State Medical University, Ministry of Health of Russia
- Issue: Vol 34, No 12 (2023)
- Pages: 30-33
- Section: Pharmacology
- URL: https://journals.eco-vector.com/0236-3054/article/view/625576
- DOI: https://doi.org/10.29296/25877305-2023-12-06
- ID: 625576
Cite item
Open Access
Access granted
Abstract
The authors discuss the treatment of chronic heart failure (CHF) and present the results of our own study on the use of dapagliflozin in combination with standard therapy in patients with CHF. The comparison group consisted of patients receiving standard therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-adrenoblockers and mineralocorticoid receptor antagonists.
Full Text
About the authors
N. V. Zaporozhskaya
Rostov State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-6370-035X
Russian Federation, Rostov-on-Don
E. A. Kartashova
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0003-0912-2568
Candidate of Medical Sciences
Russian Federation, Rostov-on-DonE. I. Zheleznyak
Rostov State Medical University, Ministry of Health of Russia
Email: musurivskaya@mail.ru
ORCID iD: 0000-0002-5165-1044
Candidate of Medical Sciences
Russian Federation, Rostov-on-DonReferences
- Kramer C.K., Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2019; 70: 323–34. doi: 10.1146/annurev-med-042017-094221.
- Wiviott S.D., Raz I., Bonaca M.P. et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 200: 83–9. doi: 10.1016/j.ahj.2018.01.012
- McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381 (21): 1995–2008. doi: 10.1056/NEJMoa1911303
- Dewan P., Jackson A., Lam C.S.P. et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail. 2020; 22 (5): 898–901. doi: 10.1002/ejhf.1776
- Solomon S.D., Vaduganathan M., Claggett B.L. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141 (5): 352–61. doi: 10.1161/CIRCULATIONAHA.119.044586
Supplementary files
